Contents

Volume 34 Issue 2 | IJGC February 2024

Lead Article

179 Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study

Cervical Cancer

203 SUCCOR morbidity: complications in minimally invasive versus open radical hysterectomy in early cervical cancer
D Velazquez-Vicente, F Borja, T Castellanos, M Gutierrez, E Chacon, N Manzour, J A Minguiez, N Martin-Calvo, J L Alazar, I Chiva, SUCCOR Study Group

209 Impact of pelvic radiation therapy in patients with early neuroendocrine cervical carcinoma and no residual disease in the radical hysterectomy specimen: a NeCTuR study
N Khurana, M Frumovitz, A Flores Legarreta, P Ramalingam, A Jhingran, P Bhosale, R Saab, N R Gonzaes, G B Chisholm, G Salvo

Editorial

188 Isolated tumor cells in low-risk endometrial cancer: are we ready for treatment decisions in ‘isolation’?
H-C Hsu, P T Ramirez

Meeting summary

198 Highlights from the 24th European Congress on Gynaecological Oncology in Istanbul: an ENYGO-IJGC Fellows compilation

Vaginal Cancer

199 TRLmodal DEFinitive invasive vaginaL carcinoma Treatment (TRIDENT protocol): how a standardized approach may change prognostic outcomes
V Lancellotta, G Mascia, G Giarrusso, B Fionda, D Pezzulli, M De Angelis, R Autorino, T Zinolica, B Gui, L Russo, S M Fragomeni, G Ferrandina, A Roviresi, E Sala, G Scambia, M A Gambacorta, L Tagliaferri

Uterine Cancer

229 Clinopathological characteristics of multiple-classifier endometrial cancers: a cohort study and systematic review
L A De Vitis, G Schivardi, G Masera, C Fumagalli, D Vicari, M T Achille, A Alessi, A Garbi, V Zanagno, G Alti, E Guerini-Rocco, A Mariani, A Maggioni, M Barberis, G Bogani, N Colombo, F Molinu, J Betella

239 PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer
A Westermann, P Oetvøs, A Reiners, J R Kroep, M G H Van Oijen, R Lalisang, P O Witeven
Contents

Volume 34 Issue 2 | IJGC February 2024

Surgery

244 Uterine smooth muscle tumors: a multicenter, retrospective, comparative study of clinical and ultrasound features
F Borrella, M Manacaria, M Preti, L Marsoni, I Stura, A Sciarrone, G Bertschy, B Lasezzi, E Piovano, G Valdegheri, M Turinetti, J Pino, I Castellano, L Bertero, P Cassoni, S Cosma, D Franchi, C Benedetto

251 Evaluation of a tiered opioid prescription algorithm in an ERAS pathway: exploring opportunities for further refinement

Ovarian Cancer

260 Attitude of BRCA1/2 mutation carriers towards surgical risk reduction for breast, ovarian and uterine cancer: still much to be done
C Nahshon, Y Segev, M Schmidt, O Lavie

267 Comprehensive molecular assessment of mismatch repair deficiency in Lynch associated ovarian cancers using next generation sequencing panel
S R Kim, L Oldfield, A Tane, A Pollett, S Pedersen, J Weltum, M Cesari, K Lajkos, T J Pugh, S E Ferguson

277 Cost-effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy in the maintenance of patients with homologous recombination deficiency-positive advanced ovarian cancer after response to first-line platinum-based chemotherapy
S Cavallini, C Cestari, S Aceto, S Manto, A C Cacci, L Minci, P Ventayol Bosch, A Casado, A Persel Felguera

285 Prognostic factors in young women with epithelial ovarian cancer: the Young Ovarian Cancer-Care (YOC-Care) study

Health & Survivorship

300 Development and clinical application of a tool to identify frailty in elderly patients with gynecological cancers
A Ferrero, R Masselino, M Villa, E Badellino, J O S P Sanjinez, M Giorgi, A Testi, F Govone, D Attianese, N Bighia

Reviews

307 Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer
P Parida, G Baburaj, M Rao, S Lewis, R D Damraula

317 The microbiome and gynecologic cancer: cellular mechanisms and clinical applications
J Chalif, H Wang, D Spakowicz, A Quick, E K Arthur, D O’Malley, L M Chambers

Clinical trial

328 Secondary cytoreduction surgery for recurrent epithelial ovarian cancer patients after PARPi maintenance: A multicenter, randomized, controlled clinical trial
T Chen, J Xu, B Xu, H Wang, Y Shen

Tumor board

332 Synchronous endometrial endometrioid adenocarcinoma and ovarian endometrioid adenocarcinoma
E Rodriguez Gonzalez, M Daeners, S Chang, A Suri

Corners of the world

339 The tug of war: delivering safe gynecologic oncology treatment amid insecurity in Haiti
C Millien, R Henderson, J J Saint Hubert, N D McKenzie, T Randall

Video articles

340 Transabdominal resection of the metastatic lymph nodes at the level of the celiac trunk
J Li, J Du, M Zhu, W Jiang
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>342</td>
<td>Not as easy as it seems: indocyanine green tracking and anatomical variations of sentinel lymph node locations</td>
<td>R P Fernandes, N R Abu-Rustum, C Anton, J P Carvalho</td>
</tr>
<tr>
<td>344</td>
<td>Complex abdominal wall reconstruction for an isolated parietal recurrence of ovarian cancer</td>
<td>M Montesinos-Albert, P-A Giroux, D Hudry, C Pasquesoone, F Narducci, C Martinez-Gomez</td>
</tr>
<tr>
<td>346</td>
<td>Myxoid leiomyosarcoma of the ovary: a very uncommon finding</td>
<td>M Sant’Angelo, A Bartolucci, L Boccidone, G Taccagni</td>
</tr>
<tr>
<td>349</td>
<td>Total uterine inversion due to pedunculated vaginal tumor</td>
<td>M H Castillo, C Marrufo</td>
</tr>
</tbody>
</table>